VYNE Therapeutics (VYNE) Competitors $3.23 +0.26 (+8.75%) (As of 05:23 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends VYNE vs. SGMT, STRO, MGX, ELUT, ADAP, FTLF, BMEA, IFRX, ALGS, and NBTXShould you be buying VYNE Therapeutics stock or one of its competitors? The main competitors of VYNE Therapeutics include Sagimet Biosciences (SGMT), Sutro Biopharma (STRO), Metagenomi (MGX), Elutia (ELUT), Adaptimmune Therapeutics (ADAP), FitLife Brands (FTLF), Biomea Fusion (BMEA), InflaRx (IFRX), Aligos Therapeutics (ALGS), and Nanobiotix (NBTX). These companies are all part of the "pharmaceutical products" industry. VYNE Therapeutics vs. Sagimet Biosciences Sutro Biopharma Metagenomi Elutia Adaptimmune Therapeutics FitLife Brands Biomea Fusion InflaRx Aligos Therapeutics Nanobiotix VYNE Therapeutics (NASDAQ:VYNE) and Sagimet Biosciences (NASDAQ:SGMT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, community ranking, valuation, risk, earnings, profitability, media sentiment and institutional ownership. Which has more volatility and risk, VYNE or SGMT? VYNE Therapeutics has a beta of 1.37, indicating that its stock price is 37% more volatile than the S&P 500. Comparatively, Sagimet Biosciences has a beta of 2.31, indicating that its stock price is 131% more volatile than the S&P 500. Do analysts rate VYNE or SGMT? VYNE Therapeutics presently has a consensus target price of $6.88, indicating a potential upside of 112.85%. Sagimet Biosciences has a consensus target price of $23.00, indicating a potential upside of 352.76%. Given Sagimet Biosciences' higher possible upside, analysts clearly believe Sagimet Biosciences is more favorable than VYNE Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VYNE Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Sagimet Biosciences 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86 Which has better earnings & valuation, VYNE or SGMT? Sagimet Biosciences has higher revenue and earnings than VYNE Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVYNE Therapeutics$493K96.64-$28.45M-$0.86-3.76Sagimet Biosciences$2M77.91-$27.88MN/AN/A Does the media refer more to VYNE or SGMT? In the previous week, VYNE Therapeutics had 8 more articles in the media than Sagimet Biosciences. MarketBeat recorded 8 mentions for VYNE Therapeutics and 0 mentions for Sagimet Biosciences. VYNE Therapeutics' average media sentiment score of 0.04 beat Sagimet Biosciences' score of 0.00 indicating that VYNE Therapeutics is being referred to more favorably in the media. Company Overall Sentiment VYNE Therapeutics Neutral Sagimet Biosciences Neutral Do institutionals and insiders believe in VYNE or SGMT? 83.8% of VYNE Therapeutics shares are owned by institutional investors. Comparatively, 87.9% of Sagimet Biosciences shares are owned by institutional investors. 4.8% of VYNE Therapeutics shares are owned by company insiders. Comparatively, 17.6% of Sagimet Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community favor VYNE or SGMT? VYNE Therapeutics received 5 more outperform votes than Sagimet Biosciences when rated by MarketBeat users. However, 96.30% of users gave Sagimet Biosciences an outperform vote while only 64.58% of users gave VYNE Therapeutics an outperform vote. CompanyUnderperformOutperformVYNE TherapeuticsOutperform Votes3164.58% Underperform Votes1735.42% Sagimet BiosciencesOutperform Votes2696.30% Underperform Votes13.70% Is VYNE or SGMT more profitable? Sagimet Biosciences has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -6,896.55%. Sagimet Biosciences' return on equity of -23.63% beat VYNE Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets VYNE Therapeutics-6,896.55% -43.73% -38.55% Sagimet Biosciences N/A -23.63%-22.91% SummarySagimet Biosciences beats VYNE Therapeutics on 11 of the 16 factors compared between the two stocks. Ad DTI[PDF] The Opportunity in GoldCommodities expert, Geof Smith, insists that the supercycle on gold is just getting warmed up. In fact, even though gold looks like this since he initially called a major bull run 11 months ago… He’s still predicting it will be the TOP trade of 2025. His free eBook explains why You see, the last time gold launched into a supercycle like this it surged 536% The time before that was over 1,000%... That’s why Geof released this urgent guide to help you. Most people think they’ve missed out, but he thinks we’re at the very beginning of what could be the largest gold rally of our lifetimes. But, believe it or not, Geof doesn’t think you should just buy and hold precious metals. He’ll share more about his approach inside the eBook and it might surprise you.Tap here to read it Get VYNE Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VYNE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VYNE vs. The Competition Export to ExcelMetricVYNE TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$47.65M$6.68B$5.24B$9.26BDividend YieldN/A2.98%5.11%4.26%P/E Ratio-3.7610.6887.6117.33Price / Sales96.64209.011,161.96123.70Price / CashN/A57.1543.3737.83Price / Book0.515.254.905.06Net Income-$28.45M$150.75M$120.44M$225.13M7 Day Performance35.15%5.56%3.94%5.93%1 Month Performance11.76%-1.92%18.94%4.09%1 Year Performance28.69%9.74%29.71%18.90% VYNE Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VYNEVYNE Therapeutics3.1888 of 5 stars$3.23+8.8%$6.88+112.8%+14.2%$47.65M$493,000.00-3.7630Analyst ForecastGap DownHigh Trading VolumeSGMTSagimet Biosciences1.8638 of 5 stars$4.99+0.8%$23.00+360.9%-10.5%$153.07M$2M0.008STROSutro Biopharma4.6678 of 5 stars$1.86-1.3%$11.13+499.7%-53.9%$152.96M$160.96M-1.15240Short Interest ↑MGXMetagenomi1.6433 of 5 stars$4.08+0.7%$16.67+308.5%N/A$152.67M$44.76M0.00236Short Interest ↑ELUTElutia2.9571 of 5 stars$4.39-9.3%$10.00+127.8%+111.8%$151.73M$24.78M-1.68180Short Interest ↓Gap DownADAPAdaptimmune Therapeutics3.0237 of 5 stars$0.59-2.6%$2.79+373.3%+15.8%$150.72M$175.04M-2.68449Short Interest ↓FTLFFitLife Brands3.4696 of 5 stars$32.25+2.6%$40.00+24.0%+52.2%$148.29M$62.76M19.0820Short Interest ↑BMEABiomea Fusion4.156 of 5 stars$4.05-4.3%$39.36+871.9%-72.0%$146.77MN/A-1.0150Short Interest ↑IFRXInflaRx2.2676 of 5 stars$2.49+11.2%$8.00+221.3%+46.8%$146.62M$168,498.00-2.3160Short Interest ↑Gap UpALGSAligos Therapeutics4.163 of 5 stars$39.63-0.5%$75.00+89.3%+124.8%$142.19M$6.00M-2.9890Short Interest ↑Positive NewsHigh Trading VolumeNBTXNanobiotix2.3476 of 5 stars$3.00-3.2%$12.00+300.0%-55.4%$141.40M$36.22M0.00100Short Interest ↑Gap UpHigh Trading Volume Related Companies and Tools Related Companies SGMT Competitors STRO Competitors MGX Competitors ELUT Competitors ADAP Competitors FTLF Competitors BMEA Competitors IFRX Competitors ALGS Competitors NBTX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VYNE) was last updated on 12/26/2024 by MarketBeat.com Staff From Our PartnersTSLA *BANG* incoming (bullet in the chamber rn)I just pinpointed 5 dirt-cheap stocks that could soar the second the shot goes off. Thanks to Donald Trump’...StocksToTrade | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredI was wrong. Dead wrong. Something is stirring deep in Silicon Valley. My team and I have been watching the tech markets closely. ...Porter & Company | SponsoredElon Musk could help pay for your retirementElon Musk is the richest man in the world... And he's pouring trillions into a unique investment.Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VYNE Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VYNE Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
